Advertisement

Muskelrelaxantien

  • Judith Günther
Chapter

Zusammenfassung

Nach wie vor entfällt der Hauptteil der Verordnungen zentralwirkender Muskelrelaxantien auf Tetrazepam (30%), Chininsulfat (24%) und Baclofen (18%).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bröse HD, Repges R, Dethlefsen U (1996): Therapie schmerzhafter Kontraktionen der Skelettmuskulatur — Doppelblinder Parallelgruppenvergleich zwischen den zentral wirksamen Myotonolytika Methocarbamol und Tetrazepam. Münch Med Wschr 138: 726–731.Google Scholar
  2. Deutsche Gesellschaft für Neurologie (2002): Leitlinie Spastik. http://www.dgn.org/130.0.html.Google Scholar
  3. Gready DM (1976): Parafon forte® versus Robaxisal® in skeletal muscle disorders: a double-blind study. Curr Therap Res 20:666–673.Google Scholar
  4. Keane RE, Simiand J, Morre M, Biziere K (1988a): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychophar-macological profile in rodents. J Pharmacol Exp Ther 245:692–698.PubMedGoogle Scholar
  5. Keane RE, Bachy A, Morre M, Biziere K (1988b): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites. J Pharmacol Exp Ther 245: 699–705.PubMedGoogle Scholar
  6. Mandai AK, Abernathy T, Nelluri SN, Stitzel V (1995): Is quinine effective and safe in leg cramps? J Clin Pharmacol 35: 588–593.Google Scholar
  7. Man Son Hing M, Wells G, Lau A (1998): Quinine for nocturnal leg cramps: a meta-analysis including unpublished data. J Gen Intern Med 13:600–606.PubMedCrossRefGoogle Scholar
  8. Middleton RSW (1984): A comparison of two analgesic muscle relaxant combinations in acute back pain. Br J Clin Pract 38: 107–109.PubMedGoogle Scholar
  9. Preston KL, Guarino JJ, Kirk WT, Griffiths RR (1989): Evaluation of the abuse potential of methocarbamol. J Pharmacol Exp Ther 248:1146–1157.PubMedGoogle Scholar
  10. Preston KL, Wolf B, Guarino JJ, Griffiths RR (1992): Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther 262: 707–720.PubMedGoogle Scholar
  11. Shakespeare DT, Boggild M, Young C (2003): Anti-spasticity agents for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.Google Scholar
  12. Simiand J, Keane PE, Biziere K, Soubrie P (1989): Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn Ther 297: 272–285.PubMedGoogle Scholar
  13. Tisdale SA, Ervin DK (1975): A controlled study of methocarbamol (Robaxin®) in acute painful musculoskeletal conditions. Curr Ther Res 17: 525–530.PubMedGoogle Scholar
  14. Valtonen EJ (1975): A double-blind trial of methocarbamol versus placebo in painful muscle spasm. Curr Med Res Op 3: 382–385.CrossRefGoogle Scholar
  15. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Kropfgans M et al (1993): Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type. Br J Pharmacol 109:360–370.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Judith Günther
    • 1
  1. 1.Freiburg

Personalised recommendations